AU2009253738B2 - Antiviral salts - Google Patents
Antiviral salts Download PDFInfo
- Publication number
- AU2009253738B2 AU2009253738B2 AU2009253738A AU2009253738A AU2009253738B2 AU 2009253738 B2 AU2009253738 B2 AU 2009253738B2 AU 2009253738 A AU2009253738 A AU 2009253738A AU 2009253738 A AU2009253738 A AU 2009253738A AU 2009253738 B2 AU2009253738 B2 AU 2009253738B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- salt
- free base
- acid
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5634108P | 2008-05-27 | 2008-05-27 | |
| US61/056,341 | 2008-05-27 | ||
| PCT/AU2009/000663 WO2009143571A1 (en) | 2008-05-27 | 2009-05-27 | Antiviral salts |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2009253738A1 AU2009253738A1 (en) | 2009-12-03 |
| AU2009253738B2 true AU2009253738B2 (en) | 2012-12-13 |
Family
ID=41376478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009253738A Ceased AU2009253738B2 (en) | 2008-05-27 | 2009-05-27 | Antiviral salts |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8580791B2 (enExample) |
| EP (1) | EP2297141B1 (enExample) |
| JP (1) | JP5469662B2 (enExample) |
| KR (1) | KR20110019759A (enExample) |
| CN (1) | CN102046621B (enExample) |
| AU (1) | AU2009253738B2 (enExample) |
| BR (1) | BRPI0912038A2 (enExample) |
| CA (1) | CA2725618C (enExample) |
| CO (1) | CO6280534A2 (enExample) |
| EA (1) | EA020455B1 (enExample) |
| MX (1) | MX2010013019A (enExample) |
| NZ (1) | NZ590286A (enExample) |
| WO (1) | WO2009143571A1 (enExample) |
| ZA (1) | ZA201009284B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG184430A1 (en) | 2010-04-15 | 2012-11-29 | Biota Scient Management | Compound for treatment of respiratory condition or disease |
| EP2585067B1 (en) * | 2010-06-25 | 2017-08-09 | Biota Scientific Management Pty Ltd | Compound for the treatment of enteroviruses |
| CN102617462B (zh) * | 2012-02-28 | 2014-02-12 | 南京大学 | 特异性抑制肌肉微小核糖核酸的化合物及其合成方法和应用 |
| BR112016029942A2 (pt) * | 2014-06-20 | 2017-08-22 | Aviragen Therapeutics Inc | composto, forma de base livre cristalina anidra, composição farmacêutica, método para fabricação de uma forma de base livre cristalina, método de tratamento de uma infecção viral, método de tratar, aliviar, prevenir ou reduzir os sintomas ou exacerbações de asma ou doença pulmonar obstrutiva crônica e método de tratamento de doença mão, pé e boca |
| CA3216679A1 (en) * | 2021-05-05 | 2022-11-10 | George R. Painter | Nucleotide and nucleoside therapeutic compositions, combinations and uses related thereto |
| WO2024192151A2 (en) * | 2023-03-13 | 2024-09-19 | Altesa BioSciences, Inc. | Method of dosing vapendavir to treat enterovirus infections |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002050045A1 (en) * | 2000-12-18 | 2002-06-27 | Biota Scientific Management Pty Ltd | Antiviral agents |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1170387B (it) | 1982-06-07 | 1987-06-03 | Glaxo Group Ltd | Composti eterociclici, procedimento per prepararli e composizioni farmaceutiche che li contengono |
| GB2162522B (en) | 1984-08-01 | 1988-02-24 | Glaxo Group Ltd | An indole derivative |
| GB9026998D0 (en) | 1990-12-12 | 1991-01-30 | Glaxo Group Ltd | Medicaments |
| US5514778A (en) * | 1993-07-01 | 1996-05-07 | Eli Lilly And Company | Anti-picornaviral agents |
| US5545653A (en) * | 1995-06-07 | 1996-08-13 | Eli Lilly And Company | Anti-viral compounds |
| US5693661A (en) * | 1995-06-07 | 1997-12-02 | Eli Lilly And Company | Anti-viral compounds |
| US5891874A (en) * | 1996-06-05 | 1999-04-06 | Eli Lilly And Company | Anti-viral compound |
| US5821242A (en) * | 1996-06-06 | 1998-10-13 | Eli Lilly And Company | Anti-viral compounds |
| AU6031898A (en) * | 1997-01-22 | 1998-08-07 | Eli Lilly And Company | Anti-viral compounds |
| EP1001767A4 (en) * | 1997-06-04 | 2001-07-04 | Lilly Co Eli | ANTIVIRAL CONNECTIONS |
| US6358971B1 (en) * | 1998-05-20 | 2002-03-19 | Eli Lilly And Company | Anti-viral compounds |
| TR200003414T2 (tr) * | 1998-05-20 | 2001-03-21 | Eli Lilly And Company | Anti-viral terkipler |
-
2009
- 2009-05-27 NZ NZ590286A patent/NZ590286A/en not_active IP Right Cessation
- 2009-05-27 AU AU2009253738A patent/AU2009253738B2/en not_active Ceased
- 2009-05-27 JP JP2011510782A patent/JP5469662B2/ja not_active Expired - Fee Related
- 2009-05-27 EP EP09753335.0A patent/EP2297141B1/en not_active Not-in-force
- 2009-05-27 MX MX2010013019A patent/MX2010013019A/es active IP Right Grant
- 2009-05-27 WO PCT/AU2009/000663 patent/WO2009143571A1/en not_active Ceased
- 2009-05-27 EA EA201001835A patent/EA020455B1/ru not_active IP Right Cessation
- 2009-05-27 CN CN200980120191.2A patent/CN102046621B/zh not_active Expired - Fee Related
- 2009-05-27 BR BRPI0912038A patent/BRPI0912038A2/pt not_active IP Right Cessation
- 2009-05-27 US US12/994,633 patent/US8580791B2/en active Active
- 2009-05-27 KR KR1020107029303A patent/KR20110019759A/ko not_active Ceased
- 2009-05-27 CA CA2725618A patent/CA2725618C/en not_active Expired - Fee Related
-
2010
- 2010-11-25 CO CO10148308A patent/CO6280534A2/es not_active Application Discontinuation
- 2010-12-23 ZA ZA2010/09284A patent/ZA201009284B/en unknown
-
2013
- 2013-09-10 US US14/023,280 patent/US9206171B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002050045A1 (en) * | 2000-12-18 | 2002-06-27 | Biota Scientific Management Pty Ltd | Antiviral agents |
Non-Patent Citations (1)
| Title |
|---|
| GENNARO A. R (editor) "Remington: The Science and Practice of Pharmacy" Volume II, 19th Edition, 1995,pp 843-1934 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009143571A1 (en) | 2009-12-03 |
| EP2297141A1 (en) | 2011-03-23 |
| CO6280534A2 (es) | 2011-05-20 |
| US20140179710A1 (en) | 2014-06-26 |
| ZA201009284B (en) | 2012-06-27 |
| AU2009253738A1 (en) | 2009-12-03 |
| CA2725618C (en) | 2016-04-12 |
| EA201001835A1 (ru) | 2011-06-30 |
| CA2725618A1 (en) | 2009-12-03 |
| JP2011520991A (ja) | 2011-07-21 |
| EP2297141A4 (en) | 2012-04-25 |
| CN102046621A (zh) | 2011-05-04 |
| CN102046621B (zh) | 2014-11-12 |
| MX2010013019A (es) | 2011-03-21 |
| BRPI0912038A2 (pt) | 2017-06-20 |
| EA020455B1 (ru) | 2014-11-28 |
| US9206171B2 (en) | 2015-12-08 |
| JP5469662B2 (ja) | 2014-04-16 |
| NZ590286A (en) | 2011-08-26 |
| KR20110019759A (ko) | 2011-02-28 |
| EP2297141B1 (en) | 2015-10-21 |
| US20110144118A1 (en) | 2011-06-16 |
| US8580791B2 (en) | 2013-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI815396B (zh) | 具有病毒增殖抑制作用之三嗪衍生物及含有其等之醫藥組合物 | |
| TWI786110B (zh) | (s)-2-乙基丁基2-(((s)-(((2r,3s,4r,5r) -5-(4-胺基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基-3,4-二羥基四氫呋喃-2-基)甲氧基)(苯氧基)磷醯基)胺基)丙酸酯之結晶形式 | |
| CA2716914C (en) | Novel crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt | |
| US9206171B2 (en) | 6-{2 -[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole bis-dihydrogenphosphate salt (1:2) | |
| CN117551030A (zh) | N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶形式 | |
| JP2022530441A (ja) | 7h-ピロロ[2,3-d]ピリミジンjak-阻害剤 | |
| KR20180015259A (ko) | S1p1 수용체-관련 장애에서의 사용을 위한 (r)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[b]인돌-3-일)아세트산 (화합물 1)의 결정성 l-아르기닌 염 | |
| JP2019526605A (ja) | 置換2−h−ピラゾール誘導体の結晶形、塩型及びその製造方法 | |
| TWI496773B (zh) | N-[2-[[(2,3-二氟苯基)甲基]硫基]-6-{[(1r,2s)-2,3-二羥基-1-甲基丙基]氧基}-4-嘧啶基]-1-三亞甲亞胺磺醯胺之新穎結晶型 | |
| JP2023512475A (ja) | 三環式pde3/pde4二重阻害剤化合物の医薬組成物 | |
| TWI889708B (zh) | 1,3,5-三衍生物或其溶劑合物之結晶及其製造方法 | |
| WO2017124949A1 (zh) | 二氢黄酮衍生物、其制备方法和用途 | |
| WO2023093861A1 (zh) | Axl激酶抑制剂的单对甲苯磺酸盐及其晶型 | |
| EA018600B1 (ru) | Новые кристаллические соли эпалрестата | |
| RU2712226C2 (ru) | Фениламинопиримидин или полиморфная форма соли фениламинопиримидина | |
| JP4940152B2 (ja) | パモ酸オランザピン二水和物 | |
| TWI870839B (zh) | 可用於降尿酸的化合物 | |
| ES2978392T3 (es) | Sal de adición del agonista del receptor S1P1 y forma cristalina de la misma, y composición farmacéutica | |
| CN114853762A (zh) | 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途 | |
| CN102408375B (zh) | 奥扎格雷钠化合物 | |
| CN104447683A (zh) | 一种稳定的比拉斯汀化合物 | |
| CN116761612A (zh) | α-1062葡糖酸盐的固体形式 | |
| JP7597771B2 (ja) | 治療のためのベンズアミド共結晶 | |
| JP2020522472A (ja) | Pkc阻害剤の固体状態形態 | |
| KR20250130617A (ko) | 스피로고리 화합물의 결정 및 이의 제조 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |